Comparative Pharmacology
Head-to-head clinical analysis: AMCINONIDE versus LIDEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMCINONIDE versus LIDEX.
AMCINONIDE vs LIDEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory cell migration and cytokine production.
Glucocorticoid receptor agonist; inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis; suppresses inflammatory cytokines and immune cell migration.
Topical: Apply a thin film to affected skin areas twice daily. Maximum 60 g per week. Use for no longer than 2 consecutive weeks.
Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.
None Documented
None Documented
Clinical Note
moderateAmcinonide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Gatifloxacin."
Clinical Note
moderateAmcinonide + Rosoxacin
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Rosoxacin."
Clinical Note
moderateAmcinonide + Levofloxacin
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Levofloxacin."
Clinical Note
moderateAmcinonide + Trovafloxacin
Terminal elimination half-life is approximately 2–4 hours, but following topical application, systemic half-life may be prolonged due to continuous absorption from the skin.
Terminal elimination half-life: 28-36 hours. Clinical context: Steady-state achieved in ~5-7 days; once-daily dosing maintains therapeutic levels without accumulation in patients with normal renal function.
Primarily renal; <5% fecal. About 40% of a dose is excreted in urine as unchanged drug and glucuronide conjugates.
Renal (primarily as metabolites) ~ 95%; biliary/fecal ~5%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Trovafloxacin."